Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02282982

Acronym

SUNRISE

Enrollment

359

Registered

2014-11-05

Start date

2014-10-31

Completion date

2015-05-31

Last updated

2016-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Syncytial Virus (RSV)

Keywords

Immunoprophylaxis, Palivizumab

Brief summary

This was a non-interventional, prospective, multi-center study with no control group designed to assess the effectiveness of palivizumab in a population of infants at high-risk of serious Respiratory Syncytial Virus (RSV) illness (infants born ≤ 35 weeks of gestation and infants ≤24 months with Bronchopulmonary Dysplasia (BPD) or Congenital Heart Disease (CHD)). Participants received immunoprophylaxis during the RSV season, defined as October 2014 through April 2015, in routine clinical settings throughout the Russian Federation.

Detailed description

Participants received intramuscular injections of palivizumab according to physicians' prescription and the local label. The local label recommended 1 month injection intervals between 5 sequential injections at a dose of 15 mg/kg. Participants could have received from 3 to 5 monthly injections of palivizumab during the 2014 - 2015 RSV season and the duration of this study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 2 Years

Healthy volunteers

Inclusion criteria

* Planned prescription of palivizumab for immunoprophylaxis during RSV season or participants for whom palivizumab was prescribed and who received the first dose of palivizumab no later than 60 days before enrollment in the study * Infants at high risk of severe RSV infection defined as fulfilling at least one of the following: * Infants born ≤35 weeks gestational age AND are ≤6 months of age at the onset of the RSV season; * Infants ≤24 months of age AND with a diagnosis of BPD (defined as oxygen requirement at a corrected gestational age of 36 weeks); * Infants ≤24 months of age with hemodynamically significant CHD, unoperated or partially corrected. * Written authorization to use individual data signed by parents or child representative

Exclusion criteria

* Major congenital malformation aside from CHD * Chronic pulmonary disease other than BPD * Acute period of any infection * Contraindication to palivizumab prescription according to local label * Administration of a product possibly containing RSV-neutralizing antibody within 30 days prior to enrollment or current administration (includes, but is not restricted to, the following: RSV hyperimmunoglobulin, polyclonal intravenous immunoglobulin, cytomegalovirus hyperimmunoglobulin, varicella zoster hyperimmunoglobulin)

Design outcomes

Primary

Measure	Time frame	Description
Proportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive Respiratory Syncytial Virus (RSV) Diagnostic Test	Approximately 7 months	Hospitalizations for LRTI with positive RSV diagnostic tests were documented at study visits.
Proportion of Infants Who Died From a Confirmed Respiratory Syncytial Virus (RSV) Infection	Approximately 7 months	Deaths caused by RSV during the study were to be confirmed by autopsy or clinical history and positive virologic diagnostic tests.

Secondary

Measure	Time frame	Description
Median Length of Stay (LOS) of Participants in the Intensive Care Unit (ICU)	Approximately 7 months	The median length of stay of hospitalized participants in the Intensive Care Unit was calculated.
Proportion of Participants Who Received Supplemental Oxygen While Hospitalized	Approximately 7 months	The proportion of participants who received supplemental oxygen while hospitalized was documented.
Proportion of Participants Who Received Mechanical Ventilation While Hospitalized	Approximately 7 months	The proportion of participants who received mechanical ventilation while hospitalized was documented.
Proportion of Participants With Missed Doses of Palivizumab	Approximately 7 months	The proportion of participants with missed or delayed doses of palivizumab was documented.
Median Length of Stay (LOS) of Lower Respiratory Tract Infection (LRTI) Hospitalization With a Positive Respiratory Syncytial Virus (RSV) Test	Approximately 7 months	The duration of hospitalizations due to LRTI which were accompanied by a positive RSV diagnostic test was documented.
Median Duration of Mechanical Ventilation Administration During Hospitalizations	Approximately 7 months	The median duration of mechanical ventilation administration during hospitalizations was calculated.
Median Duration of Oxygen Administration During Hospitalizations	Approximately 7 months	The median duration of mechanical oxygen administration during hospitalizations was calculated.
Proportion of Participants With a Particular Co-morbidity	Approximately 7 months	The proportion of participants with co-morbidities was documented. Co-morbidities were defined by the International Statistical Classification of Diseases 10 revision (ICD-10).
Proportion of Participants With Co-morbidities During Hospitalizations	Approximately 7 months	The proportion of participants with co-morbidities during hospitalizations was documented. Co-morbidities were defined by the International Statistical Classification of Diseases 10 revision (ICD-10).
Proportion of Participants With Intensive Care Unit (ICU) Admission Among Hospitalized Participants	Approximately 7 months	The number of hospitalized participants admitted to the Intensive Care Unit was documented.

Participant flow

Participants by arm

Arm	Count
Infants at High-risk of Serious RSV Illness Infants who received immunoprophylaxis during the RSV season	359
Total	359

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Death	4
Overall Study	Lack of product	156
Overall Study	Lost to Follow-up	15
Overall Study	Other, not specified	18
Overall Study	Palivizumab is ended	11
Overall Study	Withdrew consent	2

Baseline characteristics

Characteristic	Infants at High-risk of Serious RSV Illness
Age, Continuous	3.4 months STANDARD_DEVIATION 3.6
Sex: Female, Male Female	179 Participants
Sex: Female, Male Male	180 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	0 / 359
serious Total, serious adverse events	17 / 359